Article

A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas

Sheila and David Fuentes Program in Cancer Biology, Sylvester Comprehensive Cancer Center and the Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
British Journal of Cancer (Impact Factor: 4.82). 09/2009; 101(3):381-6. DOI: 10.1038/sj.bjc.6605198
Source: PubMed

ABSTRACT The cancer immunoediting hypothesis has gained significant footing over the past decade as a result of work performed using sarcomas induced by 3-methylcholanthrene (3-MCA) in mice. Despite the progress made by several groups in establishing evidence for the three phases of immunoediting (elimination, equilibrium and escape), there continues to be active controversy on the nature of interaction between spontaneously formed tumour cells and the immune system during the early phases of tumourigenesis. At the root of this controversy is conflicting and unresolved evidence spanning back to the 1970s regarding the incidence and frequency of 3-MCA-induced sarcomas in immunocompetent mice as compared to immunodeficient mice. In this mini review we provide a critical analysis of both sides of this controversy.

Download full-text

Full-text

Available from: Taylor H Schreiber, Jul 04, 2015
0 Followers
 · 
151 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: All nascent neoplasms probably elicit at least a weak immune reaction. However, the initial effect of the weak immune reaction on a nascent tumor is always stimulatory rather than inhibitory to tumor growth, assuming only that exposure to the tumor antigens did not antedate the initiation of the neoplasm (as may occur in some virally induced tumors). This conclusion derives from the observation that the relationship between the magnitude of an adaptive immune reaction and tumor growth is not linear but varies such that while large quantities of antitumor immune reactants tend to inhibit tumor growth, smaller quantities of the same reactants are, for unknown reasons, stimulatory. Any immune reaction must presumably be small before it can become large; hence the initial reaction to the first presentation of a tumor antigen must always be small and in the stimulatory portion of this nonlinear relationship. In mouse-skin carcinogenesis experiments it was found that premalignant papillomas were variously immunogenic, but that the carcinomas that arose in them were, presumably because of induced immune tolerance, nonimmunogenic in the animal of origin.
    Clinical and Developmental Immunology 07/2010; 2010. DOI:10.1155/2010/851728 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Immuntherapie und Tumorzellvakzinierung ist eine herausfordernde Therapieoption beim Prostatakrebs, zumal Nebenwirkungen nur selten auftreten. In diesem Review werden aktuelle Entwicklungen in der Vakzinierungstherapie des Prostatakarzinoms diskutiert. Die FDA-genehmigte antigenpräsentierende Zellvakzine Sipuleucel-T wird im Detail beschrieben, ebenso wie neue Strategien in der Immuntherapie wie die der RNA und Peptidvakzinierung. Derzeit ist der Erfolg einer Prostatakrebsvakzinierung immer noch mit Einschränkungen verbunden. Die immunsuppressive Wirkung des Tumors im lokalen Mikroenvironment und die Ausbildung regulatorischer T-Zellen, die das Immunsystem in seiner Effektorfunktion unterdrücken, limitieren den Therapieerfolg. Das Konzept der immunologischen „Schnittstellen-Checkpointmodulation“ beschreibt die gezielte Beeinflussung immunologischer Schnittstellen, um Toleranzmechanismen zu durchbrechen und die Immunantwort zu steigern. Mögliche klinische Mechanismen einer Checkpointmodulation werden skizziert. Immune therapy and tumor cell vaccination is a challenging option in prostate cancer therapy, especially as side effects rarely occur. This review highlights recent developments in vaccination therapy of prostate cancer. The FDA approved antigen presenting cell vaccine Sipuleucel-T is described and new strategies of immune therapy like RNA and peptide vaccination are discussed in detail. Currently the effect of prostate cancer vaccination has still limitations, at least partially due to the immune suppressive effects of the tumor microenvironment and regulatory T cells, which suppress the immune effector function. To overcome these hurdles the concept of immune checkpoint modulation, which has the aim to break tolerance mechanisms, is discussed. Potential clinical therapies of checkpoint modulation are outlined. SchlüsselwörterProstatakarzinom–Vakzinierung–T-Zell-Aktivierung–Mikroenvironment des Tumors–Sipuleucel-T KeywordsProstate carcinoma–Vaccination–T-cell activation–Specific immune therapy–Sipuleucel-T
    Der Urologe 01/2012; 51(1):44-49. DOI:10.1007/s00120-011-2712-6 · 0.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
    Seminars in Immunology 03/2010; 22(3):105-12. DOI:10.1016/j.smim.2010.02.001 · 6.12 Impact Factor